Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

NCT04956302 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped PI Decision

Conditions

Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions

DRUG: Bortezomib
DRUG: Daratumumab and Hyaluronidase-fihj
DRUG: Dexamethasone
DRUG: Panobinostat Lactate

Sponsor

Abdullah Khan